We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Rhenovia Pharma Opens First US Office

Rhenovia Pharma Opens First US Office

Rhenovia Pharma Opens First US Office

Rhenovia Pharma Opens First US Office

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rhenovia Pharma Opens First US Office"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rhenovia Pharma SAS has announced its first international subsidiary, Rhenovia Inc, incorporated in Delaware.

Rhenovia’s new operation will be based in the Greater Boston Area with offices in Cambridge, Massachusetts.

Rhenovia Inc. will enable the widespread use of its unique biosimulation technology in healthcare, with particular focus on accelerating the search for new treatments of diseases of the central and peripheral nervous system.

It will do this via its service partnership offers in the form of studies using proprietary tools such as High Throughput Search for Synergistic Drug Combinations, Numerical Pharmacological Compound Profiling, anticipation of Safety/Toxicity and Drug-Drug Interaction Risks, and alliances for the implementation of Rhenovia’s biosimulation approach in the Drug Discovery and Development Programs.

Rhenovia will also be looking to expand its emerging drug candidate pipeline as well as offering attractive investment opportunities.

”It’s the right time to intensify our commercial activity and to move closer to our major pharma and biotech clients, and academic research partners,” said Dr. Serge Bischoff, president and CEO, Rhenovia Pharma.

Dr. Bischoff continued, “It’s also time to disseminate worldwide the huge potential of Rhenovia’s breakthrough technology of modelling and simulating neuronal transmission under normal and pathological conditions in the brain, the eye, the spinal cord and muscular junction.”

While biosimulation is routinely used in almost all non-CNS therapeutic fields, such as cardiovascular or infectious diseases, oncology, asthma, or HIV, it is still an emerging technology in the field of mental, neurological, neurodegenerative and neurodevelopmental diseases.

“However, this should not be a hurdle. On the contrary it will be a great opportunity to make the search for new medications more efficient, and more generally to provide answers to major societal and economic challenges, showing Rhenovia’s technology can be applied far beyond drug discovery,” said Bischoff.

Rhenovia has already attracted partners from such diverse areas as the nutrition industry, for the prevention of diseases by optimizing food; defence ministries and organizations, to protect populations against war/terrorism neurotoxic agents; chemical and agrochemical industries and regulatory organs and stakeholders in the field of cleantech and eco-toxicity, which assess the neurological impacts of a great variety of active compounds and molecules.

“The deployment of Rhenovia in the US will accelerate our development, by helping to expand and diversify the markets for our biosimulation service offering, but also by intensifying our influence in industrial countries beyond France,” said Bischoff.

Bischoff continued, “Rhenovia will also be looking to educate the US health, economic, defence, business and financial authorities and organizations about the huge potential of our biosimulation approach in the CNS area.”

Rhenovia Inc. will provide specific, customized offers for US pharma and biotech companies to markedly increase the productivity of their R&D, to reduce costs, time-to-market and risks of failures.

It will also help US academic research groups and scientists to increase the understanding of basic mechanisms underlying diseases, while contributing more efficiently to healthcare and patients’ wellbeing.